ABSTRACT
One-fifth of patients with cancer suffer venous thromboembolic events. Although oncology patients have four to eight times more chance to develop an episode of thrombosis, 72% of these do not seem to be at a higher risk compared to the general population. The management of thromboembolic disease has specific connotations in cancer patients, necessitating independent study; oncology patients have unique risk factors due to individual patient condition and their analytical deterioration, the disease itself (which varies based on the type of cancer), and associated treatments. Prophylaxis and treatment of venous thromboembolic disease in oncology have changed a few established guidelines for nononcology patients. Furthermore, other cases, such as the diagnosis of incidental pulmonary embolism or central venous catheter, are worthy of an independent analysis.
